Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

Oxford's OMass raises $310m on foreign leads

2 min read
18:53UTC

Bain Capital Life Sciences, Forbion and Novo Holdings co-led a $310m Series C for the Oxford spinout, taking its lead drug into Phase 2.

TechnologyDeveloping
Key takeaway

Three foreign investors led OMass's $310m round while its British backers followed on.

OMass Therapeutics, a University of Oxford spinout, closed an oversubscribed $310m (about £230m) Series C in mid-October, co-led by Bain Capital Life Sciences of the United States, Forbion of the Netherlands and Denmark's Novo Holdings⁠1. Every existing investor followed, including Syncona, Oxford Science Enterprises, the British Business Bank and the university itself. Syncona disclosed a £10.1m commitment.

The money takes OMS1620 into Phase 2 trials, the first tests of whether a drug works in patients, for congenital adrenal hyperplasia and Cushing's syndrome driven by adrenocorticotropic hormone (ACTH). The drug blocks the MC2 receptor, through which ACTH tells the adrenal glands to make cortisol. Bain Capital's Evan Greif joins the board.

One round of this size equals about 8% of the £2.83bn that went into all of British life sciences in the first half of the year. As leads, the three foreign investors set the terms; the Oxford spinout's existing holders, the state bank among them, followed on.

Deep Analysis

In plain English

OMass Therapeutics is a drug company that grew out of research at the University of Oxford. It has raised $310m, about £230m, from investors. The money pays for Phase 2 trials, the stage where doctors first test whether a drug actually helps patients. The drug, OMS1620, is meant for two rare hormone conditions. In both, the body makes too much of the stress hormone cortisol or related hormones, which harms health over many years. The lead investors are from the United States, the Netherlands and Denmark. British investors put money in too, but did not lead.

Deep Analysis
Root Causes

Phase 2 trials for rare endocrine disorders cost far more than British specialist funds usually write in a single round. That gap means the price-setting cheque comes from American and continental investors such as Bain Capital Life Sciences, Forbion and Novo Holdings, which run funds large enough to lead.

OMass Therapeutics' science also fits a market that pays well. Congenital adrenal hyperplasia patients currently rely on lifelong high-dose steroids, so a drug that blocks the MC2 receptor directly would compete in a disease area where pharmaceutical buyers have already shown interest.

What could happen next?
  • Consequence

    A syndicate with crossover funds makes a public listing the likeliest next financing step for OMass Therapeutics.

  • Risk

    A failed Phase 2 readout in congenital adrenal hyperplasia would remove most of the value this round prices in.

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

Fierce Biotech· 22 Oct 2026
Read original →
Causes and effects
This Event
Oxford's OMass raises $310m on foreign leads
A single British biotech round worth about 8% of the sector's first-half funding was led from abroad.
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.